TOP2A/MCM2, p16INK4a, and cyclin E1 expression in liquid-based cytology: a biomarkers panel for progression risk of cervical premalignant lesions

Table 5 Cellular biomarkers and oxidative damage and their association to SIL and cervical cancer development

	NSIL^a	LSIL			HSIL			CC
	OR	OR	CI	p	OR	CI	p	OR	CI	p
TOP2A/MCM2	1.0	22.5	9.3–54.1	<0.001	900.8	240.3–3376	<0.001	2484	507–∞	<0.001
p16INK4a	1.0	10.1	4.6–22.2	<0.001	138.1	42.6–447.8	<0.001	320.6	75.0–∞	<0.001
Cyclin E	1.0	10.0	4.6–21.3	<0.001	109.9	36.3–333.2	<0.001	533.0	123.3–∞	<0.001
Ki-67	1.0	6.7	3.4–13.2	<0.001	121.4	40.9–360.3	<0.001	522.8	121.5–∞	<0.001
Telomerase	1.0	13.7	6.1–30.7	<0.001	85.7	26.2–280.5	<0.001	165.9	39.2–∞	<0.001
RI-5	1.0	58	18.5–186.1	<0.001	4012	755–21,323	<0.001	8290	1309–∞	<0.001
RI-4	1.0	29.5	11.3–76.8	<0.001	1482	340.8–6461	<0.001	3878	691–∞	<0.001
RI-3	1.0	40.2	14.2–114.4	<0.001	2924	592–14,429	<0.001	5913	998–∞	<0.001
RI-2	1.0	24.5	9.9–60.8	<0.001	1290	306.8–5429	<0.001	3020	526–∞	<0.001
ROS	1.0	1.8	1.4–2.3	<0.001	1.2	0.8–1.8	0.30	0.5	0.3–0.8	0.004
8-OHdG	1.0	4.4	2.7–7.2	<0.001	3.6	1.9–6.6	<0.001	5.3	2.8–10.0	<0.001

NSIL Non-squamous intraepithelial lesions, LSIL Low-grade squamous intraepithelial lesions, HSIL High-grade squamous intraepithelial lesions, CC Cervical cancer, OR Odds ratio, CI Confidence interval, RI Risk index; RI-5 analysis with TOP2A/MCM2, p16INK4a, cyclin E, Ki-67, and telomerase; RI-4 analysis with TOP2A/MCM2, p16INK4a, cyclin E, and Ki-67; RI-3 analysis with TOP2A/MCM2, p16INK4a, and cyclin E; RI-2 analysis with TOP2A/MCM2 and p16INK4a OR adjusted by age and HPV infection by oncogenic risk (HPV negative, HR, PHR, LHR, and UHR) ^areference category

ISSN: 1471-2407